How desirable are your IC50s? A way to enhance screening-based decision making

Area of Science:

• Pharmacology
• Biostatistics
• Drug Discovery

Background:

• Dose-response curves are crucial for estimating drug potency (e.g., IC50) in drug discovery.
• The reliability of these estimates directly impacts downstream applications and decision-making.
• Current methods lack a standardized, objective measure for assessing endpoint reliability.

Purpose of the Study:

• To introduce a new, reliable measure for quantifying the dependability of dose-response curve endpoints.
• To provide a consistent method for ranking and comparing experimental results in drug screening.
• To enable better integration of data from multiple experiments and guide optimal compound characterization.

Main Methods:

• Development of a novel reliability score based on Harrington's desirability concept.
• The method utilizes parameters characterizing the dose-response curve, independent of specific analysis software.
• Validation of the score's utility in ranking, data aggregation, and determining characterization levels.

Main Results:

• The proposed reliability score offers an objective and consistent metric for evaluating endpoint estimates.
• The score effectively ranks screening results, facilitating prioritization of compounds.
• It aids in combining information from multiple experiments and defining necessary levels of biological activity characterization.

Conclusions:

• The new reliability score provides a valuable tool for enhancing the rigor of drug discovery processes.
• Its application improves the interpretation and utilization of dose-response data.
• This method supports more informed decision-making in compound selection and development.